P PRIMESTOCKFINDER.COM

ADR Shares Adherium Limited

ASX · ASX
$0.07 +6.35% Prices as of close 2026-10-26

Last in our picks 2026-10-25 — not in the current list; analysis below is from that screen

Connected respiratory devices offer commercialization upside with scalable digital-health economics.

  • ▸Commercial adoption and partnership announcements could improve momentum.
  • ▾Below 50-day MA (-26.11%)
  • ▸Volume 9.79× average — accumulation
  • ▾Near 52-week low (0.5% of range)

Trend: ADR is trading below the 50-day average (-16.25%), RSI 18 — oversold territory, with a 3-month return of -36.19%.

Valuation & quality: Adherium Limited trades on forward P/E 1.3; fundamentals show net margin 0.0%, revenue growth 309.9% year on year.

Analyst consensus: 1 analysts have a mean 12-month price target of A$0.89 (+1229.5% vs the last close; range A$0.89 – A$0.89), consensus rating “none”.

Our screen: ACCUMULATE (score 1) — Connected respiratory devices offer commercialization upside with scalable digital-health economics.

Computed from end-of-day data; not personal advice.

0.42 0.06 FebMarAprMayJunJulAugSepOct
Daily close, 2026-02-08 → 2026-10-25 (AUD). Range 0.06 – 0.42.
Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26
+0.00%-20.00%+0.00%+0.00%-45.00%-9.10%-20.00%-12.50%
Market cap
$3.7M
P/E (ttm)
1.2
Forward P/E
1.3
EPS (ttm)
$0.00
Beta
1.12
Net margin
0.0%
Revenue growth
309.9%
Revenue (ttm)
$2.1M
Free cash flow
$-10,069,608
52-wk range
$0.06 – $0.67
Volume
72,078
Avg volume (3m)
25,068
Mean target
$0.89
Low
$0.89
High
$0.89
Analysts
1
Consensus
NONE
RSI (14)
17.6
vs 50-day MA
-16.25%
1-mo return
-18.29%
3-mo return
-36.19%
Volume z-score
0.61

Adherium Limited, a digital health company, develops, manufactures, and supplies digital health technologies that address sub-optimal medication use and improve health outcomes in chronic diseases.

Sector: Healthcare · Industry: Medical Devices · Australia · Website

Browse: all ASX stocks · Biotech picks · today's movers

General information only (Australia). This is general information, not financial product advice. It doesn't consider your objectives, financial situation or needs — consider its appropriateness and seek licensed advice before acting. Not a recommendation to buy or sell any financial product.

Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.